Andrew Epstein

Cooley advised LB Pharmaceuticals, a clinical-stage biopharmaceutical company developing novel therapies for the treatment of neuropsychiatric diseases including schizophrenia, on its $285 million upsized initial public offering (IPO).

Cooley advised Infleqtion, a global leader in neutral atom-based quantum technology, on its definitive business combination agreement with Churchill Capital Corp X, with the aim to accelerate Infleqtion’s mission to commercialize quantum products that provide orders of magnitude improvement in computing and precision sensing applications.

Cooley advised Wugen, a clinical-stage biotechnology company pioneering the next generation of allogeneic, off-the-shelf chimeric antigen receptor T-cell (CAR-T) therapies, on its $115 million Series C financing.

Cooley advised Hengrui Pharma, a global pharmaceutical company, on its exclusive license agreement with Braveheart Bio for HRS-1893, a small-molecule inhibitor of cardiac myosin independently developed by Hengrui Pharma with best-in-class potential.